CONMED Q1 2024: revenue up 5.7% to $312.3M; adjusted EPS $0.79 beats; guidance trimmed on FX headwinds

CONMED Corp

2024-Q1 EPS reported $0.63 revenue$312,273,000

GAAP diluted EPS $0.63 vs $0.06 in Q1 2023; adjusted EPS $0.79, up 19.7% YoY.
Revenue $312.3M (+5.7% as reported, +5.9% constant currency); domestic +7.2%, international +3.8%.
General Surgery revenue grew 8.0% as reported; Orthopedic Surgery +2.8%.
FY2024 revenue guidance lowered to $1.330-1.355B (prev $1.340-1.365B) due to ~$10M FX headwind.
Adjusted EBITDA $56.3M, margin 18.0% vs 17.3% in Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

CONMED Corp reported first quarter ended March 31, 2024 results: revenue $312.3 million.

Period: first quarter ended March 31, 2024
Revenue: $312.3 million
Result: reported results

Exact text from the filing

Florida, April 24, 2024 – CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights · Sales of $312.3 million increased 5.7% year-over-year as reported and 5.9% in constant currency. · Domestic revenue increased 7.2% year-over-year. · International revenue increased 3.8% year-over-year

View on SEC.gov

493 earnings releases filed in the last 30 days. Browse all earnings releases →

CONMED Corp filing history →

Source: SEC EDGAR

accession 0001174947-24-000582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.